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Introduction
Anticoagulation with heparin is widely accepted in patients with acute coronary heart disease or after therapeutic interventions such as thrombolysis or coronary angioplasty 113 '. The variable individual response to a standard dose of heparin is well known' 451 . One possible explanation may be an interaction of heparin with co-administered drugs. In intensive care medicine, heparin is frequently used in combination with a continuous infusion of nitroglycerin. Previous reports have suggested an attenuation of the anticoagulant effect of heparin induced by concomitantly infused nitroglycerin preparations' 6 " 81 . Based on our own observations of an increased need for heparin to maintain a therapeutic state of systemic anticoagulation in several patients with nitroglycerin infusions, this study examined a possible nitroglycerin-induced heparin resistance in vitro and with a randomized, double-blind, placebo-controlled crossover trial in healthy volunteers.
Materials and methods
The preparation of nitroglycerin used was a 0-5% solution of glycerol trinitrate in ethanol with polyoxyethylene-40-castoroil (2mg.mr') as emulgator (Trinitrosan, E. Merck, Darmstadt, Germany); the heparin used was sodium heparinate (Liquemin, F. Hoffmann-La Roche, Basel, Switzerland). Activated partial thromboplastin time (APTT, s) was performed according to the manufacturer (Aktin, Baxter Dade, DOdingen, Switzerland). Values in normal adult plasma range from 25-34 s, average 30 s. Heparin concentration (U.ml ') was measured as anti-Xa-activity* 91 using an ' . The remaining free thrombin (human thrombin, Calbiochem, Lucerne, Switzerland) was measured amidolytically on chromozym TH. All amidolytic assays were run on a centrifugal analyser (Cobas, Roche). To minimize testspecific components of variability, all assays of heparin concentration, AT Ilia, AT Illi, and HC II were performed from deep frozen plasma samples in one single run. In the range of values concerned, within-assay coefficients of variance for APTT, AT Ilia, AT Illi, HC II, and heparin concentration are 3%, 4%, 6%, and 5%, respectively. The corresponding between-assay coefficients of variance are 5%, 7%, 9%, 12%, and 11%.
IN VITRO STUDY
Heparin was added to pooled, platelet-poor citrate plasma obtained from drug-free donors aiming at a final concentration of 0-3 U.ml" 1 . Trinitrosan was added, resulting in nitroglycerin concentrations from 001 ug.ml ' to lOOug.ml" Volunteers were male students (n = 7, mean age 28+4 years, weight 77+ 8 kg, platelet count 235 000 ± 54 000.ml" 1 ) with no history of coagulation disorders or thromboembolic disease. After obtaining baseline values of coagulation parameters, nitroglycerin (100 ng.min" 1 ) and saline 0-9%, respectively, were infused in a randomized, double-blind, crossover sequence. Fifteen minutes after the start of the infusion 40U.kg~' heparin were injected as a bolus. Five, 30, 60, 90, and I80min after heparin injection, blood was drawn for coagulation tests. Infusion and blood sampling were performed through two different venous cannulas, one in each forearm. After return of coagulation parameters to baseline values the infusion was changed. After an equilibration period of 15 min the trial was repeated with the same volunteer.
The study was approved by the local review committee for human research, and informed, written consent was obtained from each volunteer.
Statistical evaluation was done by Student's t-test for paired values and two-way analysis of variance. A twotailed /"-value of <005 was considered statistically significant.
Results
In-vitro results are summarized in Table 1 placebo are shown in Fig. 1 . There was no significant difference at any time APTT was measured. Baseline values of APTT were identical, and peak values after heparin were in the therapeutic range in all subjects. Heparin concentration was not affected by the nitroglycerin infusion (Fig. 2) . At no time did the activities of antithrombin IN and heparin-cofactor II change under nitroglycerin infusion (Fig. 3) ; the same was true for the concentration of antithrombin III measured immunologically (data not shown). No side effects from heparin bolus injection or nitroglycerin infusion were observed.
Discussion
The clinical importance of an interaction of heparin with infused nitroglycerin is evident. Frequent laboratory testing and dose adjustments of heparin in patients under nitroglycerin would be mandatory. The risk of bleeding complications after discontinuation of a nitroglycerin infusion would call for a dose reduction of heparin. A nitroglycerin-induced 'heparin-resistance' may be explained by various mechanisms: (a) direct interaction on a molecular basis (b) formation of a nitroglycerinplasmaprotein-complex inactivating the negatively charged heparin like protamin (c) depletion of coagulation inhibitors mediating the heparin effect (d) influence on heparin elimination or metabolism by nitroglycerin.
Absence of nitroglycerin-induced heparin resistance 413
The results presented do not support the assumption of a clinically relevant nitroglycerin-induced heparin resistance. The in-vitro results rule out a major direct molecular interaction of the two drugs. The absence of an alteration in extent or duration of the anticoagulant effect of a heparin bolus monitored by APTT in a double-blind, placebo-controlled trial with crossover design strongly denies any important in-vivo interaction within the first 3 h after heparin injection. Heparin concentrations as well as the activities of the two major mediators of heparin effects remained unchanged, thus ruling out a substantial depletion of these factors by simultaneously infused nitroglycerin within the period investigated and with the drug preparations used.
These results contrast with previous reports which suggested a nitroglycerin-induced heparin resistance 16 " 81 . However, these observations described an attenuated heparin effect after several hours or even days of continuous, intravenous administration of both drugs'
7181
. A gradual change in metabolism of heparin or a functional depletion of AT III or HC II induced by nitroglycerin after longer periods of simultaneous infusion of both drugs remains possible. Our in-vivo experiment only investigated the immediate heparin effect. In the period of approximately 3 h with a measurable heparin effect after bolus injection, no interaction with nitroglycerin was observed.
A dose-response curve may be desirable to exclude definitely an in-vivo heparin-nitroglycerin interaction. A longer period of concomitant infusion of both drugs and higher doses of nitroglycerin might result in an attenuated heparin effect. However, nitroglycerin concentrations tested in the in-vitro experiment by far exceed plasma concentrations achieved by infusion rates used in clinical practice"
31
. As a dose-dependent effect was absent in vitro, we chose to use only one common, therapeutic dosage in the in-vitro trial (lOOug.min" 1 ) and believe a clinically relevant effect was sufficiently ruled out. Furthermore, we were concerned about submitting volunteers to higher doses of intravenous nitroglycerin.
Another limitation of this study may be the fact that for ethical reasons we only tested healthy volunteers. Different results in patients with an active thromboembolic disease such as unstable angina cannot be ruled out. However, this seems unlikely as a recent investigation in patients undergoing coronary angioplasty also failed to show any significant nitroglycerin-induced heparin resistance 1161 . The nitroglycerin preparations used in clinical practice may be of importance, too. In particular, the solvent propylene glycol has been # incriminated as the substance inducing heparin resistance'
61
. Since the preparation we used contains polyoxyethylene-40-castoroil as a nonionic emulsifying agent this could account for the differences in results. However, this seems unlikely, as both propyleneglycol-containing and propylene-glycol-free nitroglycerin preparations have been reported to attenuate heparin effects' 7 -81 .
In conclusion, an immediate nitroglycerin-induced heparin resistance with a propylene-glycol-free nitroglycerin preparation was absent in vitro and in an in-vivo trial with healthy volunteers. An attenuation of the anticoagulant effect of heparin by nitroglycerin in patients with active thromboembolic disease or after a prolonged period of concomitant intravenous administration of both drugs cannot be ruled out. The clinical importance of such an interaction calls for further studies.
